|
|
Vaccine Detail
|
ALVAC-CEA (VCP248) |
| Vaccine Information |
- Vaccine Name: ALVAC-CEA (VCP248)
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007242
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: CEA
- CEACAM5 (CEA)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: ALVAC-CEA B7.1 is a canarypox virus encoding the gene for the tumor-associated antigen carcinoembryonic antigen (CEA) and for a T-cell costimulatory molecule, B7.1 (von et al., 2001).
- Description: A replication-defective recombinant canarypox virus (ALVAC) that contains the entire human carcinoembryonic antigen (CEA) gene. Vaccination with ALVAC-CEA (VCP248) may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against CEA-positive tumor cells, thereby decreasing tumor growth. (NCI04) (NCIT_C2743).
|
| Host Response |
|
|
| References |
NCIT_C2743: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2743]
von et al., 2001: von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001; 7(5); 1181-1191. [PubMed: 11350882].
|
|
